Core Points - Polyrizon Ltd. has regained compliance with Nasdaq listing requirements, allowing it to continue trading under the ticker symbol "PLRZ" [1][2] - The company demonstrated compliance with the minimum bid price requirement as per Nasdaq Listing Rule 5550(a)(2) [2] Company Overview - Polyrizon is a biotechnology company focused on developing intranasal products, specifically innovative medical device hydrogels delivered as nasal sprays [3] - The company's proprietary technology, Capture and Contain TM (C&C), creates a hydrogel-based barrier in the nasal cavity to protect against viruses and allergens [3] - Polyrizon is also developing Trap and Target TM (T&T) technology for the nasal delivery of active pharmaceutical ingredients (APIs) [3]
Polyrizon Regains Compliance with Nasdaq Listing Requirements